Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...

美国食品药品监督管理局 (FDA) 已批准对可手术的 IIA 期至 IIIB 期 NSCLC 患者进行新辅助 nivolumab 联合化疗，随后进行辅助 nivolumab 治疗，这一结果得到了 2023 年 ESMO 大会上公布的 3 期 ...

"主要的信息是，在免疫检查点阻断后，癌症免疫治疗中的代谢适应可能是相关的，"Toni K. Choueiri医学博士说。代谢过程是机体内维持生命所必需的化学反应，如将食物转化为能量以运行细胞过程。

Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...

Post-surgical adjuvant nivolumab (Opdivo) improved survival outcomes in muscle-invasive bladder cancer (MIBC), regardless of ...

Nivolumab plus cabozantinib improved long-term efficacy and safety vs sunitinib in advanced renal cell carcinoma, per final ...

Efficacy of nivolumab plus ipilimumab in T1aN0M0 renal cell carcinoma (RCC) patients: Results from 3-year follow-up of the phase 2 pilot study. Efficacy outcomes with belzutifan versus everolimus by ...

(HealthDay News) — For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer (BC), adding nivolumab to ...

Nivolumab plus cabozantinib provides long-term benefits over sunitinib in advanced RCC, according to final results from CheckMate 9ER.

Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients wi ...